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POPULAR SCIENCE SUMMARY OF THE THESIS 
The central nervous system (CNS) is the part of the nervous system including the brain and 
spinal cord. Microglia are local immune cells in the CNS. They are essential for normal CNS 
functions by responding to foreign agents and dangers. However, uncontrolled chronic 
activation of these immune cells can trigger CNS disorders including multiple sclerosis (MS). 
The cause of MS remains largely unknown, but it is commonly acknowledged that different 
immune cells play a role in the development of MS. In MS, the over-active immune cells 
(including microglia) do not recognize normal CNS proteins as being self-proteins and attack 
them. Are there potential novel therapeutic strategies by precisely targeting or replacing these 
over-active immune cells in our CNS? 
In Study 1 we developed a mouse model to remove microglia completely from the CNS for 
around one week. Subsequently, new microglia appeared and gradually filled in the empty CNS. 
At around one month, the mouse CNS was equipped again with the new healthy microglia. 
This mouse model reveals a potential means of replacing dysfunctional microglia with 
functional microglia in the human CNS. We found that the newly replaced microglia were 
derived from two different sources, proliferating CNS microglia and monocyte-derived 
microglia. 
In Study 2 we tested if the newly replaced microglia could influence MS progression by using 
the same mouse model. We firstly depleted microglia, then waited for one month until new 
microglia had populated the CNS. We then induced a MS-like disease model in these mice. To 
our surprise, we found that the newly replaced microglia made MS mice more sick. 
Interestingly, this only happened in female mice. This study thus demonstrates sex-dependent 
effects of microglia on MS development. 
In Study 3 we discovered a novel but minor subset of microglia in our microglia depletion 
mouse model. During the period of microglial replacement following depletion, the new subset 
of microglia proliferated rapidly and accounted for a significant proportion of the total 
microglial pool. As this subset has previously been overlooked, our results raise a cautionary 
note regarding the use of these mice in studies of microglial depletion and replacement. 
In Study 4 we tested if some other types of immune cells in the blood and different organs 
would be affected when we deplete CNS microglia using currently available methods (either 
gene editing or drugs). This is a contentious and less studied topic, since it is generally believed 
that microglia depletion methods are specifically targeted for microglia. However, our results 
clearly showed that other types of immune cells, including blood and splenic monocytes, were 
also influenced. These findings remind researchers to be more careful when considering 




Microglia are predominant tissue resident macrophages within the central nervous system 
(CNS), and contribute to both CNS development and homeostasis. During disease conditions 
microglia undergo transcriptional re-programming and their dysfunction is implicated in a 
multitude of disorders, such as multiple sclerosis (MS). How microglia could be therapeutically 
targeted is a current research focus. Recent experimental microglial depletion methods using 
conditional genetic targeting and pharmacological therapies have broadened our perspective of 
these multi-tasking microglia. Newly repopulated microglia following experimental microglial 
ablation hold great promise for reducing neuroinflammation and treating a variety of 
neurological disorders.  
In Study 1 our results indicated that microglia could be ablated (approximately 95%) by 
systemic use of tamoxifen in Cx3cr1CreER/+Rosa26DTA/+ mice. Microglial repopulation ensued 
through both the proliferation of surviving microglia in the CNS, and from the infiltration of 
Ly6Chi monocytes. Under this condition infiltrating monocytes could be shaped into microglia-
like cells by the CNS microenvironment. Furthermore, isolated newly repopulated resident 
microglia and infiltrating microglia-like cells following experimental depletion exhibited 
differential functionality in vitro, such as phagocytic capacity and cytokine production. 
In Study 2 we used the microglial depletion and repopulation model mentioned above and 
demonstrated that the presence of infiltrating microglia-like cells following ablation could 
exacerbate experimental autoimmune encephalomyelitis (EAE) symptoms in 
Cx3cr1CreER/+Rosa26DTA/+ female mice. This was not evident in male mice, indicating a 
potential sex effect. Under this condition there was a higher expression of major 
histocompatibility complex class II and a greater secretion of proinflammatory cytokines 
during the acute period in the female mice.  
In Study 3 we discovered a novel subpopulation of microglia that escape the genetic 
modification of Cx3cr1 in Cx3cr1CreER-EYFP/+Rosa26DTA/+ mice. Following microglial depletion 
using tamoxifen, newly repopulated Cx3cr1highEYFP– microglia had an advantage over 
Cx3cr1CreER-EYFP/+ and Cx3cr1lowEYFP+ microglia. We also found that microglial repopulation 
was tightly regulated by the CX3CL1-CX3CR1 signaling. The numbers of repopulated CNS-
resident microglia were significantly decreased, while the numbers of infiltrating microglia-
like cells were increased during repopulation in mice devoid of Cx3cr1. 
In Study 4 we demonstrated that experimentally removing microglia using both 
Cx3cr1CreER/+Rosa26DTA/+ mice and PLX3397 treatment had crucial effects on circulating 
monocytes and splenic macrophages, a finding that had previously received little attention. We 
therefore proposed that clinical translation of preclinical studies using microglial depletion 
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Since the scientific characterization of microglia using silver carbonate staining by Pio del Rio-
Hortega a century ago [1, 2], the heterogeneity and complex function of this glial cell 
population within the central nervous system (CNS) has been exponentially investigated using 
advanced technologies [3-7]. Microglia, highly specialized tissue macrophages in the CNS, 
have a unique origin and distinguishing features [8]. The timing of microglial ontogeny and the 
unique local environment in the CNS place them in a special niche when compared with 
hematopoietic stem cell-derived tissue macrophages [9, 10]. Specifically, microglia develop 
from primitive yolk sac progenitors during the embryonic period and colonize the CNS before 
formation of the blood brain barrier [11]. The unique yolk sac origin of microglia is further 
supported by requirement of transcription factor Pu.1 and independence from the transcription 
factor Myb [8, 12].  
Under physiological conditions microglial numbers are properly maintained by the 
balance of local proliferation and apoptosis without contribution from peripheral immune cells 
in both adult mice and human brain [13]. The proliferative capacities of microglia vary widely 
across different brain regions [14], and recent progress has provided novel insights that some 
microglia live for 20 years in our body [13, 15]. Without doubt, recent research advances have 
changed our historic view of these cells, with in vivo imaging of microglia demonstrating that 
microglia are extraordinarily dynamic rather than remaining stationary, constantly surveying 
the microenvironment [16], shaping CNS development and interacting with their neighboring 
elements such as neurons [17], astrocytes [18, 19], oligodendrocytes [20] and neural stem cells 
[21] (Figure 1). Isolated microglia lose their specific signatures after several hours in vitro, 
while transplanted microglia into the mice brain may re-acquire their cellular identify due to 
local environmental cues [9]. Isolated microglia in culture conditions may thus not reflect the 





Figure 1: The multi-tasking microglia in the CNS. Reprinted with permission from Han et al, 
Glia. 2019 Feb;67(2):217-231. 
Comprehensive single-cell transcriptional analysis across species has revealed that 
microglia have conserved morphology and transcriptional signatures in most species, while 
human microglia exhibit substantial heterogeneity [22]. Microglia can eliminate presynaptic 
and postsynaptic structures, phagocytosis debris, dead cells and neurons, produce various 
soluble factors [23] and migrate toward areas of injury [24]. Microglia can contribute to the 
forgetting of remote memories in the adult hippocampus through complement-dependent 
synaptic elimination, as evidenced using microglia-depleted CD11b-DTR mice as well as 
PLX3397-treated mice, which showed higher freezing levels than the control group after 
training sessions (contextual fear conditioning) [25]. Microglia can function as antigen 
presenting cells of bacterial or self-antigens (e.g. myelin) following upregulation of major 
histocompatibility complex (MHC) class II [26, 27] due to activation, the levels of which are 
low or absent during homeostasis [28]. Microglia do more than contribute to development and 
respond to injury, and emerging investigations suggest that microglia can also perform a variety 
of tasks in our brain such as regulating satiety [29]. 
In order to exercise their multiple critical functions, a number of receptors such as toll-
like receptors and scavenger receptors are expressed on microglia [30]. The CX3C chemokine 
ligand 1 (CX3CL1)-CX3CR1 signaling and CD200-CD200R axis have been considered as the 
main forms of bidirectional microglia-neuron communications [31]. The signals derived from 
neuronal-derived factors are crucial for microglial maintenance. It has recently been 
convincingly demonstrated that both mice and human microglial processes can communicate 
with specialized nano-architectural somatic microglia-neuron junctions under non-
inflammatory conditions, and that these are triggered by changes of neuronal activities and 
neuronal mitochondrial ATP production [17]. Murine microglia during waking conditions are 
less alert to the environment when compared to microglia in anesthetized conditions, since 
microglial process surveillance is tightly controlled by neuronal activity through noradrenergic 
signalling [32-34]. Growing evidence provides us with a broader and better understanding of 
how microglia take rapid actions under physiological conditions. It is important to note that 
most of our updated knowledge regarding microglia arise from rodent studies, and that some 
differences between rodent and human microglia may exist. 
1.1.1 Microglia in disease 
Microglia are considered as the first line defense against any injury of the CNS. In response to 
different brain insults microglia undergo morphological transformation with or without 
proliferation [35], alter gene expression and surface markers [36], present antigens and release 
cytokines, chemokines, cell adhesion molecules, reactive oxygen and nitrogen species. Upon 
stimulation microglia switch their metabolic features from oxidative phosphorylation to 
glycolysis in order to rapidly provide energy by generating ATP and to meet demands for 
cellular proliferation [37, 38]. Anti-inflammatory microglia/macrophages decrease their 
glucose consumption and utilize more oxidative metabolism for the function of tissue repair 
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[38]. Modulating microglial immune metabolism could thus serve as a potential means for 
reprogramming cellular activity in disease [39].  
The activation of innate immune responses is now considered to be of major 
pathophysiological significance during neurological diseases [40] such as viral encephalitis 
[41], Huntington's disease [42], hereditary diffuse leukoencephalopathy with axonal spheroids 
[43, 44] and neuromyelitis optica spectrum disorder [45]. A broad repertoire of receptors is 
expressed on microglia [30], enabling them to sense extracellular signals via the pattern 
recognition receptors, which facilitates their recruitment into injury sites. Conditional depletion 
of P2Y12R on microglia leads to increased neuronal excitability and innate fear responses in 
mice [46]. Dynamic microglial responses are apparent during disease, rather than simple 
phenotypical changes, with multiple clusters of cells existing depending on brain regions and 
disease status [36]. Microglial homeostasis gene signatures such as tmem119 and p2ry12 can 
be decreased during inflammation. Furthermore, several genes  (e.g. apoe and trem2) identified 
by genome-wide studies are associated with increased risk for neurological diseases and are 
highly expressed on disease-associated microglia [47]. Our colleagues have demonstrated that 
microglia undergo rapid and transient transcriptomic changes following a single dose of 
radiation when measured by single-cell RNA sequencing, suggesting a narrow time window 
for targeting microglia post-irradiation [48]. 
Accumulating evidence thus supports that microglia are central players and promising 
targets for treating CNS disorders [49, 50]. During cerebral hypoperfusion reactive microglia 
are redistributed in the striatum, adhering and phagocytosing the myelin components, then 
worsen white matter injury partly caused by upregulated complement C3, while either 
inhibiting C3aR or depleting microglia prevents the impairment [51]. It is important to note 
that microglia are highly adapted to brain-specific tissue microenvironments [52, 53] and are 
functionally modified through epigenetic modifications [54], the microbiome [55] and physical 
exercise [56]. In an animal model of sepsis, proinflammatory microglial markers in the 
hippocampus were significantly upregulated 24 hours after inducing sepsis, while the 
upregulation of both proinflammatory and anti-inflammatory markers co-existed for a long 
time period (30 days after inducing sepsis) [57]. The historically used classification of M1 
(proinflammatory) and M2 (anti-inflammatory: M2a, M2b, M2c or M2d) polarized states in 
vitro [58] is now considered less valid [59], as the activation states vary between individual 
cells. Targeting molecular signaling pathways and microenvironmental factors controlling 
microglial expression, rather than their activation states, may thus be a more reasonable 
therapeutic approach. 
1.1.2 The CX3CL1-CX3CR1 signaling pathway 
CX3CL1 is a chemokine predominately synthesized by neurons in the CNS [60]. Emerging 
evidence suggests that there are two different forms of CX3CL1, including a membrane-bound 
form and a soluble cleaved form, that have distinct activities [61]. CX3CR1 is the fractalkine 
receptor for CX3CL1 which is mainly expressed on microglia in the CNS. Activation of 
CX3CR1 leads to cellular signal transduction including kinase (ERK)/mitogen-activated 
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protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) 
pathways [60]. The CX3CL1-CX3CR1 signaling pathway is now considered to be a critical 
regulator of cross-communication between neurons and microglia. For example, the CX3CL1-
CX3CR1 axis plays a vital role in cell-to-cell virus transmission, as evidenced by CX3CR1 
antagonists inhibiting virus transmission from microglia to neighboring cells in a co-cultured 
system [62]. Cx3cr1, a highly expressed gene in microglia, plays a profound role in microglial 
functions and is widely used as a driver in gene reporter constructs, such as in Cx3cr1Cre mice 
or Cx3cr1CreER-EYFP/+ mice [52]. It has been demonstrated that microglial Cx3cr1 deficiency in 
young mice results in a microglial transcriptome similar to that of an aged microglial phenotype, 
suggesting that Cx3cr1-deficient microglia accelerated the aging process [63]. 
1.1.3 The TGFβ signaling pathway 
Transforming growth factor-beta (TGF-β) is a well-documented factor for microglial identity 
[64] and both TGF-β1 and TGF-β2 are highly expressed on microglia [9]. The expression of 
TGF-β in CNS tissues is significantly reduced during the peak of experimental autoimmune 
encephalomyelitis (EAE), an animal model of multiple sclerosis (MS), while TGF-β receptors 
remained unaffected [65]. Additional administration of TGF-β cytokine can reduce EAE 
disease severity [65]. We have previously indicated that long-term absence of Tgfbr2 in 
CX3CR1+ monocyte-derived macrophages causes a fatal paralysis disorder evidenced by 
proinflammatory myelin-laden giant macrophages throughout the mouse spinal cord [66], and 
this is further supported using distinct models [67, 68]. These results suggest that TGF-β 
signaling may serve as a potential therapeutic target for demyelinating diseases. 
1.1.4 The TREM2 signaling pathway 
TREM2, a key receptor selectively expressed on myeloid cells, is now viewed as a profound 
regulator that switches the homeostatic microglial state into a disease-associated phenotype. 
Genetic variants in TREM2 may confer a risk for Alzheimer's disease in early life through 
subcortical alterations [69]. Higher cerebrospinal fluid levels of soluble TREM2 at baseline, 
serving as a valuable biomarker, is associated with reduced hippocampal volume and disease 
progression in patients with Alzheimer's disease [70]. The presence of human microglial 
TREM2 mutations causes obvious metabolic deficits by decreasing the oxygen consumption 
rate and reducing glycolytic capacity, suggesting that functional loss of TREM2 in microglia 
results in failure to perform the metabolic switch and to allow a rapid supply of energy [37].  
The modulation of microglial TREM2 function within a suitable time window may benefit 
patients who are suffering from neurodegenerative diseases. Both aope and trem2 have been 
viewed as major genetic risk factors for Alzheimer's disease. TREM2 can recognize a variety 
of ligands [71], and the recently identified TREM2-APOE pathway can function as a major 
mediator of suppressing microglial normal functions during neurodegenerative diseases [72]. 
TREM2 and DNAX-activating protein of 12 kDa (DAP12), mainly expressed on microglia, 
are causative genes for Nasu-Hakola disease that is characterized by early neurodegeneration 
in the white matter and bone lesions. The TREM2/DAP12 complexes can be formed, 
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consequently phosphorylating ITAM, recruiting Syk kinase, activating related downstream 
molecules and then regulating microglial activity [71]. 
1.1.5 Uncovering microglial sexual dimorphism: More still to be explored 
It is well documented that there are multi-faceted sex differences of the brain and its behavior 
in both mice and humans [73]. Importantly, sex differences of microglia and their potential 
implications in disease have only recently become understood [74-76]. The impact of sex 
differences on microglial functions and properties are mainly through sex-specific hormonal 
signals, while microglia in turn participate in brain sexual differentiation [77].  
It is well documented that neurodevelopmental diseases demonstrate a male bias in 
incidence [78]. Male microglia may be more immature in several brain regions since their 
development is later than in females [79, 80]. However, it is important to note that there are no 
consistent data showing sex-dependent effects in neonatal and adult animals in brain-based 
disease conditions. Previous studies reported that early sex differences of microglial responses 
following ischemic stroke were noted in neonatal mice, evidenced by increasing microglial 
immunoreactivity, more pro-inflammatory markers and infiltrating myeloid cells in male mice 
after inducing ischemic stroke [81]. Minocycline can protect against male neonatal ischemia 
by modulating microglial phenotypes, but this is not the case in female mice [82]. Our 
colleagues have demonstrated that neonatal microglia-depleted male Cx3cr1CreER/+Rosa26DTA/+ 
mice exhibited significantly larger infarct volumes and a higher rate of apoptotic neurons 
following hypoxic ischemia than in Cx3cr1CreER/+ female mice [83].  
Microglial sexual dimorphism following immune responses is likely to be time-dependent. 
These sex differences can also be influenced by estrogens, the levels of which in the circulation 
may vary with age and reproductive states [73]. Sex has been viewed as a prominent contributor 
of microglial interactions, with amyloid plaques in the EFAD mice model of Alzheimer's 
disease (a model that carries human APOE alleles) in female mice showing lower microglial 
plaque coverage and TREM2 levels than in the males [84]. Using inducible 
Cx3cr1CreER/+Rosa26DTA/+ mice to deplete adult microglia we have determined that the 
infiltration of microglia-like cells following ablation exerts sex-specific effects on EAE in adult 
mice, with female adult mice experiencing a more serious disease course than do males [85]. 
It has been reported that Escherichia coli infection in the periphery significantly decreased 
brain-derived neurotrophic factor (BDNF) expression in the male rat cerebellum, but not in the 
females [86]. Early-life infection can increase IL-6 expression in the female cerebellum, but 
not evidence in males [86]. The BDNF-TekB-dependent pathway potentially influenced by 
estrogen may account for these microglial functional sex differences, to some extent, as 
supported by distinct correlations between BDNF mRNA levels and depressive-like behaviors 
between males and females being evident in a chronic mild stress model [87]. Although there 
are no overall differences in microglial numbers in the rat periaqueductal gray matter between 
males and females, more amoeboid microglia are located at this region in females compared to 
males, and lower proinflammatory cytokines transcription was noted following systemic 
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lipopolysaccharides (LPS) challenge [88]. Furthermore, the microbiome can also exert 
significant effects on microglial properties in a sex-dependent manner [55, 89]. 
1.1.6 Future directions and challenges in microglial research 
The development of new genetic animal models such as Tmem119-EGFP and Tmem119-
CreERT2 mice that could target the resident microglia with a high specificity would improve 
our understanding of microglial biology [90]. In addition, specific microglia diagnostic 
methods, such as measuring soluble TREM2 in the cerebrospinal fluid, or neuroimaging of 
microglial signaling pathways, might facilitate the early detection of individuals at a high risk 
[35]. Furthermore, future microglial research needs to take potential differences between males 
and females into consideration. 
Microglia are not easily accessed in patients. Several radioligands for positron emission 
tomography (PET) have been developed in order to noninvasively monitor neuroinflammation 
and microglial activity in patients. Specifically, the [11C] PK 11195 PET tracer selectively 
binds to the mitochondrial translocator protein (TSPO). It is widely considered as a biomarker 
for neuroinflammation, interacting with reactive oxygen species and the NLRP3 
inflammasome, and being upregulated expression during glial activation [91]. A degree of 
caution is needed when interpreting inconsistent results because TSPO as a microglial marker 
has additional expression on other glial cells (e.g. astrocytes) and fails to distinguish between 
these during complex activated glial states in distinct diseases. Recently, the novel PET tracer 
[11C] SMW139 was developed as a radioligand for P2X7R (a member of purinergic type 2 
receptor family) and as an in vivo marker of neuroinflammation [92]. [11C] SMW139 has a 
high affinity to P2X7R expressed on pro-inflammatory microglia [92]. However, our 
preliminary results indicated that the radioligand for P2X7R may also not be specific for 
measuring microglial activation since P2X7 binding can be still widely noted following 
microglial depletion in Cx3cr1CreER/+Rosa26DTA/+ mice (Figure 2). Such approaches for 
measuring microglia are thus currently limited due to low cell type specificity. Potential 
differences in P2X7R expression between mice and humans should thus not be ignored [93].  
Since small molecules for P2Y12 do not cross the blood–brain barrier, there are no 
available PET radioligands for this target as yet. Recently, [11C] CPPC, a novel high-affinity 
PET radiotracer for macrophage colony stimulating factor-1 (CSF-1) receptor has been 
investigated in both animal and human disease conditions [94]. The signal intensity of brain 
uptake of [11C] CPPC was positively associated with EAE disease severity and regional 





Figure 2: Immunofluorescent staining of P2X7 (green) and Iba1 (red) in the brains of 
C57BL/6NTac wild type mice (without tamoxifen), Cx3cr1CreER/+Rosa26DTA/+ mice and 
Cx3cr1CreER/+ mice with three consecutive subcutaneous tamoxifen injections. 
1.2 MONOCYTES 
Both technological and ethical issues limit researchers to conduct research of fresh human 
microglia. Circulating monocytes are much easier to sample than human microglia obtained 
after autopsy [95]. Monocytes are critical mediators of the innate immunity [96]. Unlike 
embryonic yolk sac derived-microglia in the CNS [11], monocytes are of peripheral origin and 
account for approximately 10% of circulating human leukocytes [96]. Under physiological 
conditions peripheral immune cells are restricted from entering the CNS by multiple barriers 
such as the blood-brain barrier. However, monocytes can be recruited into the CNS 
parenchyma when the blood-brain barrier is compromised during disease conditions, thereafter 
developing into either macrophages or dendtiric cells with specialized functions [97]. 
Monocytes can be moblizated rapidly in order to perform inflammatory effector and regulation 
functions at inflamed sites [96]. Furthermore, peripheral monocytes may modulate other 
myeloid cell activities in the CNS [98]. In mice, infiltrating monocytes/macrophages can be 
reprogramed in the brain following ischemic stroke, upregualting efferocytosis-related genes, 
phagocytizing dead neurons and thus contributing to inflammation resolution [99]. 
Circulating human monocytes are a heterogeneous cell type that can be subdivided into 
three different subpopulations based on the expression of CD14 and CD16, denoted as classical 
monocytes, non-classical monocytes and intermediate monocytes. Classical monocytes 
(CD14++CD16-) account for 80-90 % of human blood monocytes, highly express CCR2 (an 
important mediator of monocyte migration) and display inflammatory properities. Non-
classical monocytes (CD14+CD16+) account for 2-10 % of human blood monocytes and highly 
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express CX3CR1. Intermediate monocytes (CD14++CD16+) account for the remaining 
component and express either CCR2 or CX3CR1. It is suggested that these three isolated 
monocyte subsets produce different levels of cytokines following stimulation [96]. Circulating 
monocytes play a crucial role in mediating systemic inflammation during diverse disease 
conditions [100]. For example, PD-1+ circulating monocytes (mainly intermediate monocytes) 
may serve as a potential biomarker for predicting vasospasm in patients with subarachnoid 
hemorrhage, as evidenced by PD-1+ circulating monocytes being increased before the presence 
of radiographic vasospasm and correlating with the cerebral blood flow velocities [101]. In a 
preclinical model of subarachnoid hemorrhage, the systemic administration of soluble PD-L1 
could prevent cerebral vasospasm, mainly via inhibiting the migration of PD-1+ circulating 
monocytes into the brain [101]. Individual functional properties of these different monocyte 
subpopulations during disease conditions remain unclear, and more efforts are thus needed. 
Various aspects such as age and circadian rythms should not be ingored. 
Circulating monocytes are differently defined in mice based on the expression of Ly6C 
and chemokine receptors, denoted as Ly6Chi inflammatory monocytes and Ly6Clo monocytes  
[102]. A gating strategy of mice circulating monocytes is presented in Figure 3. 
 
Figure 3: Gating strategy for circulating mouse monocytes. 
1.3 EXPERIMENTAL MICROGLIAL DEPLETION 
Microglial ablation through pharmacological treatments or conditional genetic depletion is now 
viewed as a powerful approach to induce novel microglial repopulation of the CNS niche, as 
we have previously reviewed [49, 103, 104]. CSF1R plays a crucial role in microglial survival 
and proliferation [105, 106]. This is a receptor tyrosine kinase and mediator of myeloid lineage 
cells and is predominately expressed on microglia in the CNS [107, 108]. Both CSF-1 and IL-
34 ligands are crucial for microglial homeostasis [109]. Microglia can be experimental ablated 
in csf1r-deficient mice, while lacking the CSF-1 ligand only causes a moderate reduction of 
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microglial numbers [109]. Furthermore, the absence of CSF-1 in NesCreCsf1fl/fl mice results in 
loss of cerebellar microglia, but not forebrain microglia, reducing Purkinje cells, increasing 
cerebellar volume and causing motor learning and sociability changes [109]. Some studies 
reported that activated microglia may be less dependent on the CSF1R signaling, but definitive 
proof is lacking as yet [110]. 
Pharmacological targeting of CSF1R using compounds such as PLX3397 or Pexidartinib 
(Plexxikon Inc.) [51], PLX5622 (Plexxikon Inc.) [111], BLZ945 (Novartis) [112] or GW2850 
[113] has increased in popularity as a means to deplete microglia in research settings, such as 
mixed glial cultures [114] and animal models [115]. These compounds are usually integrated 
into rodent chow diet and do not have harmful effects on mice health and growth in adults [25]. 
Although diet-based PLX3397 (290 mg/kg) and PLX5622 delivery for ablating microglia is 
commonly used in current research, it may have limitations in depletion effectiveness for 
preweaning or sick mice due to reduced appetite. Intraperitoneal injection or 
intracerebroventricular injection of CSF1R inhibitors should thus be considered in research 
settings. In order to achieve a faster and higher efficiency, a higher concentration of PLX3397 
(400 mg/kg) can also be used, resulting in around 90% microglial ablation in 7 days [110]. Cell 
death within the CNS can occur through apoptosis and phagocytosis [19], but the precise 
cellular mechanisms controlling experimental microglia death are not completely understood.  
Microglial depletion using PLX3397 did not significantly alter adult mice behavioral 
performance, as measured by the elevated plus maze and open field tests [25], while ablating 
microglia during the neonatal period using liposomal clodronate causes long-term changes of 
locomotion and decreased anxiety and despair behaviors [116]. Although most previous studies 
reported no obvious side-effects after microglial depletion in adults [117], it is important to 
note that microglia also provide trophic or metabolic support in the CNS [23] and some 
potential effects following microglial depletion should not be ignored in research settings. For 
example, the electrical threshold of spreading depolarization elicitation can be significantly 
changed after microglia depletion using PLX5622 treatment [118].  
Microglia-mediated injury is considered as a leading driver of neurodegeneration [110]. 
In diverse disease conditions microglial depletion has a broad range of beneficial results, 
mainly by reducing neuroinflammation [49]. However, the use of current experimental 
microglial depletion methods has yielded mixed results since immunological responses of 
microglia to CNS injury are complex in both space and time aspects. Removing microglia using 
PLX5622 decreased mRNA expression of Nox2 in the nucleus accumbens and prevented the 
anxiety behavior caused by nicotine withdrawal [119]. It has been reported that treatment of 
PLX3397 increased the rate of myelination and decreased the rate of nerve fiber destruction 
and the extent of the gaps formed between layers of myelin sheaths in a cuprizone-induced 
demyelination mouse model [115]. The rapid administration of CSF1R inhibitor PLX5622 
after cell isolation in vitro effectively depletes microglia but required a relatively long 
incubation time since potential CSF-1-resistant microglia may exist in the culture from the very 
beginning [114]. The advent of more specific microglial markers and novel tools could provide 
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more clarity. Specifically targeting disease-associated microglia in neurological diseases 
within a suitable time window may be a potential immunotherapy for diverse neurological 
diseases [47]. 
1.4 MICROGLIAL REPOPULATION HOLDS PROMISE FOR DISEASE 
THERAPY 
Microglia can rapidly repopulate following their depletion owing to their self-renewal ability, 
occurring only 1 day after withdrawal of CSF1R inhibitors [120]. Newly repopulated microglia 
can either stem from infiltrating microglia-like cells [52, 97] or solely from CNS-resident 
microglia [121, 122], depending on different models and the efficiency of microglial depletion.  
Newly engrafted microglia-like cells following selective microglia depletion exhibit 
different gene expression and functions when compared with CNS-repopulated resident 
microglia [52]. This point was further supported by later studies, demonstrating that two 
different sources of myeloid cells including peripheral macrophages contribute to the 
compensation of microglial numbers independently of irradiation [97]. Microglia and 
microglia-like cells may thus contend for the colonization of the empty niche in the CNS, and 
microglia-like cells can outcompete CNS resident-microglia if resident microglia lack the 
capacity for CX3CL1-CX3CR1 signaling (our unpublished observations).   
From the perspective of cell therapy, bone marrow-derived cells have different functions, 
such as clearance of amyloid beta [123]. A combined administration of intravenous and 
intramuscular bone marrow mononuclear cells exhibited beneficial effects in the SOD1G93A 
amyotrophic lateral sclerosis mouse model by delaying disease onset and decreasing spinal 
cord microgliosis [124]. These pre-clinical results remind us to take different cell sources and 
routes of administration into consideration when designing potential microglial replacement 
therapy, especially in settings of neurodegenerative diseases such as incurable CSF1R-related 




Figure 4: Potential microglial replacement therapy for CSF1R-related leukoencephalopathy. 
Reprinted with the permission from Han et al, Acta Neuropathologica Communications. 2020 
Dec 7;8(1):217. 
In experimental spinal cord injury condition, we have found that homeostatic spinal cord 
microglia undergo permanent transcriptional re-programming and transform into the disease-
associated microglia, as assessed by single cell RNA-sequencing (our unpublished 
observations). One recent study reported that a combination of gelatin hydrogel transplantation 
and PLX3397 treatment could better improve disease recovery in a spinal cord injury mice 
model than does single PLX3397 treatment, mainly through replacing CD68+ reactive 
microglia and the presence of newly repopulated microglia in the spinal cord [120].   
1.5 MULTIPLE SCLEROSIS  
MS is a multifocal demyelinating disease of the CNS mainly caused by environmental cues 
which act on genetically susceptible young individuals, causing irreversible cumulative 
neurological disability [125]. Diverse immune cells, neuronal and axonal loss, all likely 
contribute to distinct pathogenic processes in MS [126, 127]. Apart from marked demyelinating 
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lesions in the CNS, normal-appearing white matter is also implicated in disease pathogenesis 
and can be affected by the hypothalamus-pituitary-adrenal axis activity [128]. Remarkable 
progress has been made in disease-modifying therapies of MS during recent years. The history 
of disease-modifying therapies for MS started from injectable interferon beta-1a to oral 
immunomodulating therapies and new monoclonal antibodies targeting B cells [129]. The 
widely used immunotherapies for MS have been proven effective to decrease the annual relapse 
rate and to reduce new lesions. Early treatment for MS appears to decrease the total relapse 
over a long time period, especially during the first year after treatment. Most randomized 
controlled trials exclude MS patients aged more than 55 years old, and it remains challenging 
for managing these ageing individuals with MS due to unique age and MS-related 
comorbidities in clinical practice [130]. Currently, an expanding array of treatments for 
relapsing-remitting MS are available, and therapeutic options for adult progressive MS are also 
emerging [131]. However, a recent Phase IIb clinical trial demonstrated that potential 
neuroprotective drugs including Amiloride, Fluoxetine and Riluzole do not reach any primary 
or secondary outcomes over 96 weeks in British MS patients [132]. 
Among commonly used disease-modifying therapies for MS, Fingolimod has been 
reported to exert the strongest impact on peripheral immune cell frequencies using a highly 
standardized approach [133]. Cladribine has a long-term effect on peripheral immunity [129]. 
Monitoring circulating peripheral immune cells and opportunistic infections can be helpful for 
managing MS in clinical practice [134]. The right choice of disease-modifying therapies for 
MS depends on balancing expected efficacy, safety and tolerability [129].  
The novel identification of serum/plasma neurofilament as predictors of clinical 
progression are broadening our perspective to predict and monitor disability in MS [135]. The 
baseline degree of plasma neurofilament is positively associated with the clinical Expanded 
Disability Status Scale score and clinical cognitive performance, and importantly, their level 
can be dramatically reduced by Alemtuzumab treatment [136]. Application of 7 Tesla MRI 
further expands our understanding of cerebral leptomeningeal enhancement and gray matter 
involvement in MS patients [137]. Microglial activation is a major driver of cortical 
demyelination. MS patients with high inflammatory profiles of cortical lesions measured by 
PET and 7T MRI having a worse clinical outcome than those with low cortical inflammation 
patients [138]. Although T cells and B cells have been intensively investigated in MS, less is 
known about the roles of other immune cells such as myeloid cells. Circulating monocyte 
numbers during the early MS period could serve as a potential candidate biomarker for 
predicting subsequent disease severity [139].  
1.6 MOG-EAE 
Despite many limitations to represent the pathogenesis of MS, EAE is still a commonly used 
animal model. EAE can be induced by passive transference of auto-reactive CD4+ T cells or 
through active immunization with a myelin antigen emulsified in Complete Freund’s Adjuvant 
(CFA). Myelin oligodendrocyte glycoprotein (MOG) is a minor protein that is expressed on 
the outermost lamella of the myelin sheath [140], and MOG33-55 serves as the most popular 
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antigen emulsified in CFA for inducing EAE in C57BL/6 background mice [141], especially 
as many research used gene specific knockout mice have been generated on this background 
[142]. Additional injections of pertussis toxin are also required to inhibit peripheral T cell 
anergy induction and to increase the permeability of the blood-brain barrier [143]. The first 
signs of MOG-EAE after immunization are weight loss and obvious clinical symptoms such as 
tail weakness and paralysis of hind limbs can be observed around 10 days after immunization 
[144].  
In clinical practice, antibodies against MOG will directly target oligodendrocytes and the 
myelin sheath, which is associated with a wide variety of clinical presentations including optic 
neuritis, transverse myelitis and encephalitis [145]. Serum MOG-lgG1 antibodies are 
recommended to be preferentially detected using live cell-based assays, and high titers or 
persistent seropositivity of MOG-lgG antibodies may predict a relapsing disease course. It is 
firmly established that MOG-antibody associated disease, with less female predominance, is 
quite different from MS regarding immunopathological targets, clinical features and magnetic 
resonance imaging (MRI) findings [146]. Furthermore, a poor response to some MS drugs has 
been noted in some cases, while most patients with MOG-antibody-associated disease respond 
well to corticosteroids and intravenous immunoglobulins, often with full recovery [147]. 
Importantly, abundant phagocytic CD68+ infiltrating macrophages (negative for Tmem119) 
and CD8+ T cells in the gadolinium-enhancing brain lesion had been noted in one patient with 
histopathologically confirmed MOG-antibody-associated disease [148].  
Some argue that MOG-antibody-associated disease is quite different from MS  [149-151]. 
The complex pathogenesis of MS replies on a combination of genetic diversity, epigenetic 
modifications, environmental factors and a variety of immune cell types [152], while its animal 
models fail to represent the entire spectrum of disease characteristics. Furthermore, 
immunological processes of MS progression in humans are distinct from the animal model, 
sometimes causing disappointment when translating preclinical findings into the clinic. For 
example, non-selective blocking tumor necrosis factor-α (TNF-α) showed beneficial outcomes 
in EAE, which was detrimental for patients with MS [153]. It reminds us to choose suitable 
experimental animal models in order to test specific hypotheses in MS and to optimize the 
communication between basic and clinical research. 
1.7 MICROGLIA AS A THERAPEUTIC TARGET FOR MS AND ITS ANIMAL 
MODEL 
Inflammation contributes to the demyelination and tissue injury in both acute and progressive 
stages of MS [154]. Pathological studies suggested that microglial activation is most 
pronounced in active MS lesions, while microglial numbers are decreased in inactive MS 
lesions [154]. A diversity of microglial activation states as measured by single-cell RNA 
sequencing include previously characterized disease-associated microglia [155], and aging-
associated microglia are noted in an acute local demyelination mice model, without any overlap 
of clear-cut M1 and M2 gene profiles [156]. Microglia are also enriched for a variety of MS 
susceptibility genes, which was convincingly indicated by a recent genomic map [157]. 
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Dimethyl fumarate, the first line oral clinical treatment for MS in the clinic, may exert its 
neuroprotective activity by modulating microglial phenotypes and functions [158]. 
Several studies have demonstrated that removing microglia has beneficial effects on EAE 
and in the cuprizone demyelination model  [112, 159, 160]. Another study inferred an opposite 
conclusion, that ablating microglia by administration of tamoxifen in 
Cx3cr1CreERRosatdTomRosa26iDTR mice causes higher accumulation of infiltrating macrophages 
in spinal cord lesions [156]. The application of microglia-specific therapeutic strategies bears 
great promise for CNS regeneration, particularly in progressive MS [161]. Microglia serve as 
a double-edged sword in MS pathology, either by exacerbating demyelination or by clearing 
myelin debris [162].  
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2 MATERIALS AND METHODS 
Animal models 
Cx3cr1CreER and Rosa26DTA mice were purchased from the Jackson Laboratory, and bred in the 
KI animal house facility in order to obtain Cx3cr1CreER/+Rosa26DTA/+ and Cx3cr1CreER/+ mice 
(Figure 5), which were used in studies 1, 2 and 4.  
 
Figure 5: An overview of breeding strategies used in studies 1, 2 and 4.  
The second generation Cx3cr1CreER/+R26, Cx3cr1CreER/+R26DTA/+, Cx3cr1CreER/CreERR26 and 




Figure 6: An overview of breeding strategies used in study 3.  
Cx3cr1GFP/GFP mice breeding pairs were purchased from the Jackson Laboratory and 
C57BL/6NTac mice were received from Taconic.  
Generation of bone marrow chimeras  
Bone marrow chimeric mice were generated by irradiating mice with 9.5 Gray with head 
protection and then reconstituting on the same day with 2-5 x 106 bone marrow cells via tail 
vein injection (used in studies 1 and 3). The mice were used in experiments at 6-8 weeks post 
reconstitution. 
Tamoxifen treatment 
Tamoxifen was suspended in corn oil at 75°C for at least 60 min. Ault mice were administered 
5mg (200μl) tamoxifen subcutaneously on three consecutive days, and then kept for varied 
durations to allow different degrees of microglial repopulation [52, 66] in studies 1, 2 and 4. In 
study 3, 125 mg/kg or 62.5 mg/kg tamoxifen was injected i.p for three (postnatal days 18, 19 
and 20) or ten consecutive days (postnatal days 18–27). 
PLX3397 treatment 
PLX3397 (Pexidartinib, HY-16749, MedChemExpress) formulated into the standard diet (75 
mg/kg and 290 mg/kg) was administered for different durations. Control mice were fed with a 




Study 1: To develop an effective microglial depletion animal model followed by long-term 
microglial repopulation with a combination of resident microglia and engrafted microglia-like 
cells 
 
Study 2:  To investigate the effects of engrafted microglia-like cells after microglial depletion 
on autoimmune neuroinflammation 
 
Study 3:  To study the CX3CL1-CX3CR1 signaling pathway regulating microglial repopulation 
after conditional genetic microglial depletion 
 
Study 4:  To explore potential peripheral effects following both conditional genetic and 

















4 RESULTS AND DISCUSSION 
The main purpose of this PhD project was to assess the role of microglia in homeostasis and 
disease. This was accomplished by developing a novel conditional genetic model 
(Cx3cr1CreER/+Rosa26DTA/+ mice) for depleting microglia with a higher efficiency, and by using 
the CSF1R inhibitor PLX3397. When the microglial niche was made available following 
experimental depletion, we explored if peripheral engrafted microglia-like cells could also 
contribute to the microglial pool during homeostasis. We then studied if replacing microglia 
during disease conditions could serve as a potential therapeutic strategy for MOG-EAE, and its 
sex difference, signaling pathways as well as potential adverse effects. The four manuscripts 
included in the thesis represent the combined efforts to test the hypothesis that modulation of 
microglial functional is both a critical underlying factor in pathogenesis, and also represents a 
viable therapeutic modality.  
4.1 STUDY 1 
Background: Microglia are the main resident immune cells in the CNS and are derived from 
the yolk sac during early development. Microglia can maintain their numbers during 
homeostasis by local self-renewal, without contribution from the periphery. The microglial 
niche theory has been proposed recently, suggesting that each microglia occupy its own 
physical space and that these niches can become available during experimental microglial 
depletion [163]. 
Hypothesis: Competitive microglial repopulation starts once the microglial niche is made 
available. 
Methods: In this study Cx3cr1CreER/+Rosa26DTA/+mice were systemically administered 
tamoxifen to deplete microglia due to intracellular DTA expression upon Cre recombination in 
CX3CR1-expressing cells. Microglial depletion and repopulation were mainly measured using 
flow cytometry and immunohistochemistry. 
Results: We observed that approximately 95% of CD11b+CD45+Ly6C–Ly6G– microglia could 
be depleted in Cx3cr1CreER/+Rosa26DTA/+ mice 7 days after tamoxifen administration by flow 
cytometry. The findings were further supported by microglia-specific P2ry12 and CX3CR1-
YFP immunostaining. Twenty-eight days later new microglia had partly repopulated the CNS 
of Cx3cr1CreER/+Rosa26DTA/+ mice, with two distinct cell subsets within the CX3CR1+ gate 
differentially expressing F4/80. Most resident microglia in Cx3cr1CreER control mice did not 
express a high level of F4/80. F4/80hi peripherally-derived macrophages were P2ry12–. We then 
demonstrated that the repopulated microglia had dual origins, including yolk-sac derived 
microglia which proliferated locally and infiltrating Ly6Chi monocytes which transformed into 
microglia-like cells within the CNS microenvironment. Embryonic yolk-sac derived microglia 
and microglia-like cells exhibited distinct functions in vitro.  
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Reflections: This study gave me a great opportunity to get involved in the hot research field of 
microglial depletion and to learn flow cytometric analyses. I also learned the breeding strategy 
of Cx3cr1CreER/+Rosa26DTA/+ mice which were used in subsequent projects.  
In paper I we developed a novel conditional genetic method to deplete microglia long-lastingly 
and to make the microglial niche available. We concluded that following this experimental 
microglial depletion method peripheral monocytes could access and then adapt to the CNS 
microenvironment, becoming monocyte-derived microglia-like cells. Full transformation to 
bona fide microglia was excluded through transcriptional and epigenetic analyses, and these 
cells remained functionally different to embryonic yolk-sac derived microglia.  
The unique identity of microglia is critically dependent on both ontogeny and the CNS niche-
specific microenvironment [10]. Previous studies have provided evidence that microglial 
numbers can be maintained through their proliferation within the CNS, with no input from the 
periphery during homeostasis [13]. Importantly, the novel microglial niche theory suggests that 
each microglial cell occupies its physical space within the CNS [163, 164]. Temporarily 
available niches of microglia are evident in some conditions, which is tightly regulated [165]. 
During experimental microglial depletion as a result of tamoxifen treatment in 
Cx3cr1CreER/+Rosa26DTA/+ mice, peripherally-derived monocytes could acquire microglia-like 
gene expression profiles and adopt microglia-like DNA methylation signatures, so that these 
microglia-like cells exhibited a partially different gene signature compared to resident 
microglia. In support of our findings, others have reported that peripherally-derived microglia-
like cells can engraft the brain independently of irradiation in Cx3cr1CreER/+Csf1rFlox/Flox mice 
[97]. 
Available surface markers assessed by flow cytometry for differentiating resident microglia 
and microglia-like cells lack the required level of specificity. For example, the expression of 
CD45 can be altered during inflammation [166]. F4/80 staining is also not a commonly 
accepted marker to discern microglia from peripheral colonizers of the CNS, either. To address 
these concerns, in paper I we performed a kinetic assessment of microglial depletion, 
demonstrating that Ly6Chi circulating monocytes have already entered the CNS two days after 
the start of tamoxifen treatment, before the establishment of the microglia-like cells. 
Furthermore, adoptive transfer of Ly6Chi monocytes into the microglia-depleted mice could 
cause specific reconstitution of the F4/80hi microglia-like cell pool. Collectively, peripherally-
derived cells could significantly refill the microglial niche following microglial depletion with 
a high efficiency in Cx3cr1CreER/+Rosa26DTA/+ mice.  
In addition, microglia were isolated from the CNS tissues into a single-cell suspension using 
both mechanical and enzymatic dissociations in order to facilitate culture or analyses. However, 
these methods may alter microglial activation status and ex vivo microglia may lose their key 
signature genes and coordinated cell-to-cell communication. We also discerned that yolk-sac 
derived resident microglia and infiltrating microglia-like cells exhibited different functions, 
such as phagocytic capacity and cytokine production in vitro. One previous study has 
demonstrated that transplantation of bone marrow-derived microglia-like cells led to an 
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increased phagocytic uptake of amyloid-β in an Alzheimer's mouse model, subsequently 
reducing amyloid-β burden and improving cognitive function [123]. However, the complicated 
roles of repopulating engrafted microglia-like cells in other disease conditions are not 
completely understood.  
4.2 STUDY 2 
Background: MS is a chronic demyelinating disease, predominantly in women. A wave of new 
research has proven that microglia exhibit sex-dependent features and play a vital role in the 
pathophysiology of MS. Microglia can be efficiently removed following conditional genetic 
depletion, with repopulating cells deriving from both CNS local microglia and the engraftment 
of microglia-like cells.  
Hypothesis: Microglial replacement followed by experimental depletion represents a potential 
means of resolving neuroinflammation in MS. 
Methods: Microglia were depleted by injection of tamoxifen to Cx3cr1CreER/+Rosa26DTA/+ mice, 
and retained for one month until new microglia had populated in the CNS. The MOG-EAE 
model was then induced in these microglia-repopulated mice. Myeloid cell populations were 
primarily assessed using flow cytometry. 
Results: We demonstrated that the engraftment of microglia-like cells following conditional 
genetic ablation exacerbated EAE in female mice, but not in male mice. Female 
Cx3cr1CreER/+Rosa26DTA/+ mice had a higher chronic disease severity than male mice, while no 
sex-dependent EAE disease severity was noted in Cx3cr1CreER/+ control mice. Our results also 
indicated that increased MHCII expression and cytokine production contributed to the sex-
dependent severity in female mice with the engraftment of microglia-like cells. 
Reflections: This study gave me a chance to plan and conduct animal studies independently. I 
learned how to induce the MOG-EAE model and how to monitor the clinical symptoms. I 
became proficient at flow cytometrical analysis, including both extracellular and intracellular 
stainings. I also realized that gender should be considered as a biological variable in both 
research and clinical settings. 
In paper II, we again used the Cx3cr1CreER/+Rosa26DTA/+ mouse model developed from paper I 
and further demonstrated that engrafting repopulating microglia-like cells reduced their ability 
to limit neuroinflammation when compared to self-renewing bona fide microglia. The 
peripherally-derived microglia-like cells thus perpetuate EAE disease and inhibit disease 
recovery. Furthermore, these effects were sex-dependent, with female mice experiencing worse 
EAE clinical symptoms, which is an interesting finding considering the female preponderance 
of MS in humans. 
We are beginning to appreciate that the role of microglia is sexually dimorphic in the condition 
of pain, as evidenced by microglia only being involved in mediating pain hypersensitivity in 
males but not in females [167, 168]. It has now been gradually established that the numbers 
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and phenotypes of microglia in the CNS generally differ between females and males [74, 75]. 
Specifically, obvious sex differences in microglial numbers have been reported in several brain 
regions including the cortex, amygdala, hippocampus and preoptic area [75]. Furthermore, sex 
differences of microglia have also been noted at both RNA and protein levels [75]. From a 
functional viewpoint, male and female microglia may have different functions, since female 
rat neonatal microglia had both less basal and stimulated microglial migration than did male 
microglia [169]. Microglia may also exhibit sex differences in phagocytic capacity during 
development [170].  
In clinical settings, sex differences of microglia may also exist and contribute to disease 
pathogenesis. For example, CSF1R-related leukoencephalopathy, caused by the CSF1R gene 
mutations, is now recognized as a primary CNS microgliopathy with dysfunctional microglia 
playing a critical role [171-173]. CSF1R-related leukoencephalopathy in women develop 
clinical signs significantly earlier than do men [174].  
The sex differences of EAE severity were not attributed to different mouse strains used in the 
study. We observed that both male and female Cx3cr1CreER/+Rosa26DTA/+mice and C57BL/6 
mice developed similar EAE courses in conditions without the involvement of microglial 
depletion and repopulation. We additionally demonstrated that the sex-dependent EAE severity 
of mice with infiltrating microglia-like cells may be partially due to increased MHCII 
expression and cytokine secretion in the female CNS. However, these findings could not 
completely explain the apparent differences in clinical symptoms, and further studies are 
needed to explore the mechanisms of microglial sex differences in neuroinflammatory 
conditions. 
4.3 STUDY 3 
Background: Microglial depletion using either pharmacological treatment or conditional 
genetic mouse models has broadened our knowledge. However, currently available genetic 
depletion approaches including Cx3cr1CreER/+Rosa26DTR mice, Cx3cr1CreER/+Rosa26DTA/+ mice 
and Cx3cr1CreER/+Csf1rFlox/Flox mice do not completely deplete microglia in the CNS, with some 
microglia remaining unabated after depletion. 
Hypothesis: CX3CR1– microglia may exist in the mouse brain and this subpopulation of 
microglia have a competitive advantage over newly repopulated microglia following 
experimental depletion.  
Results: We reported a unique Iba-1+Tmem119+EYFP– microglial subset in the brain of 
Cx3cr1CreER-EYFP/+ mice under normal conditions. Isolated CX3CR1+EYFP– microglia did not 
express Eyfp and Cre mRNA, suggesting that they may escape the Cre-mediated recombination 
in Cx3cr1CreER-EYFP/+Rosa26DTA mice. Our results demonstrated that this unique microglial 
subpopulation has a competitive advantage over newly repopulated resident microglia 
following microglial depletion. 
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Reflections: This study gave me a chance to set up a collaboration beyond our own lab. 
Teamwork in science is of great importance. This study also enabled me to master further 
experimental skills such as immunohistochemistry and microscopical analysis. I learned that 
we should not limit ourselves to only using surface markers for phenotyping in the field of 
immunology. 
In paper III we described a unique Iba-1+Tmem119+EYFP– subset with a microglial 
morphology in the brains of Cx3cr1CreER-EYFP/+ mice under homeostatic conditions. In order to 
further confirm that these YFP– microglia-like cells were not an anomaly of distinct mouse 
strains, we additionally discovered that Iba-1+Tmem119+GFP– microglia-like cells were also 
evident in the brains of Cx3cr1GFP/+ mice. This unique microglial subpopulation could 
competitively repopulate the CNS following microglial depletion, and we determined that this 
process was tightly regulated by the CX3CL1-CX3CR1 signaling.  
CX3CR1 is commonly used to label microglia by inserting EYFP or EGFP tags. In paper III 
we discovered that EYFP– or GFP– microglia may escape or silence the genetic modification 
and are not be ablated following tamoxifen treatment in Cx3cr1CreER-EYFP/+ mice or Cx3cr1GFP/+ 
mice. Although we do not completely understand the biological consequences of this 
phenomenon, our conclusion is that researchers should be cautious in their interpretation when 
these transgenic mice are applied in disease conditions. 
We also discerned that this unique microglial population can also repopulate the CNS, 
independently from self-proliferating CNS resident microglia and microglia-like cells, as a 
result of experimental microglial depletion in Cx3cr1CreER/+Rosa26DTA/+ mice. This process was 
tightly regulated by the CX3CL1-CX3CR1 signal transduction pathways. The CX3CL1-
CX3CR1 pathway is now considered as a critical regulator of cross-communication between 
neurons and microglia. One previous study indicated that the repopulation of microglia in the 
retina can be delayed in the condition of CX3CR1 deficiency, while it can be enhanced after 
the administration of exogenous CX3CL1 [165]. We further demonstrated that resident 
microglia in the brain fail to compete with the peripherally-derived microglia-like cells 
following depletion in Cx3cr1–/– mice, suggesting that the repopulation of CNS resident 
microglia rather than peripherally-derived microglia-like cell repopulation is critically 
dependent on the CX3CL1-CX3CR1 pathway. Our study provides potential clues as to how to 
modulate the process of microglial repopulation in therapeutic efforts in different disease 
conditions.  
4.4 STUDY 4 
Background: Current microglial depletion approaches are usually based on microglial markers 
such as CX3CR1 and CSF1R. A wave of new research has demonstrated that microglial 
depletion can exert neuroprotective effects in diverse disease models by reducing 
neuroinflammation. However, other immune cells may also express these markers and 
potential additional targets during microglial depletion have not been comprehensively studied. 
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Hypothesis: Microglial depletion using current available approaches exerts effects on 
peripheral immune cell populations. 
Results: We demonstrated that microglia can be effectively ablated after administering 
tamoxifen to Cx3cr1CreER/+Rosa26DTA/+ mice, or the CSF1R inhibitor PLX3397 to C57BL/6 
mice. Numbers of red pulp macrophages and Ly6Chi monocytes in the spleen were significantly 
reduced during the microglial depletion period using both genetic and pharmacological 
depletion approaches. However, in the spleens of Cx3cr1CreER/+Rosa26DTA/+ mice the number 
of monocytes was significantly higher than at baseline level. Ly6Chi monocytes in the 
circulation were also affected during microglial depletion using both genetic and 
pharmacological approaches.  
Reflections: This study gave me a chance to further explore microglial depletion using two 
different methods, including a conditional genetic mice model and using CSF1R inhibition. I 
also learned that current available methods to deplete microglia may still have disadvantages 
and potential side-effects after depletion which need to be considered in the future studies. 
In paper IV we recorded that microglial depletion using a conditional genetic mouse model and 
pharmacological approaches has significant effects on circulating monocytes and splenic 
macrophages. CX3CR1 is predominately expressed on microglia in the CNS. However, non-
classical monocytes in the circulation may also express CX3CR1. We found that both classical 
and non-classical monocyte numbers in the circulation are reduced in 
Cx3cr1CreER/+Rosa26DTA/+ mice after tamoxifen treatment. Although tamoxifen treatment itself 
causes a low-level systemic inflammation with an increased level of circulating Ly6G+ 
neutrophils, non-classical Ly6Clow monocytes are more affected than classical Ly6Chi 
monocytes under this condition. We also observed that the levels of splenic Ly6Chi monocytes 
are higher during the microglial depletion period (7 days after tamoxifen treatment) than at the 
baseline level, while a decreased level of red pulp macrophages was noted in the spleen during 
this period. 
Expression of CSF1R is mainly enriched on microglia in the CNS and is crucial for their 
survival of microglia. Use of a diet containing CSF1R inhibitors such as PLX3397 or PLX5622 
can ablate most microglia in preclinical models. However, CSF1R may also be expressed on 
circulating monocytes and peripheral tissue macrophages. For example, a high dose of 
PLX3397 (400 mg/kg) can alter the blood cell phenotyping [110], with red blood cells, 
haemoglobin, platelets, dendritic cells and Ly6C– monocytes being reduced following 
PLX3397 treatment [110]. Furthermore, one previous study provided evidence that the weight 
of the spleen was decreased after PLX3397 treatment in mice [175]. We now report that the 
levels of splenic red pulp macrophages are significantly decreased following PLX3397 
treatment (290 mg/kg). These peripheral effects of microglial depletion could be attenuated 
using a lower dose of PLX3397 (75 mg/kg).  
Collectively, our results suggested that CSF1R inhibitors are not CNS specific. The translation 
of microglia depletion into the clinic should be considered with caution, particularly in disease 
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5 FUTURE PERSPECTIVES 
We strive to apply potential novel treatment strategies from preclinical studies into clinical 
settings. We hope to develop more effective and safe microglia-specific therapeutics for 
neurological diseases. 
It is still difficult to specifically target microglia, perivascular macrophages or choroid plexus 
macrophages due to the unavailability of unique targeting markers. Microglia may exhibit 
broader phenotypes in different disease conditions, depending on the microenvironment. There 
is mounting evidence that disease-associated microglia could be either beneficial [155] or 
detrimental [176] for disease. Better selective characterization of disease-associated microglia 
within a suitable time window using novel technologies will help us to decipher their complex 
functions in disease and then to develop potential microglia-targeted therapies.  
Recent technical progress allows researchers to generate microglia-like cells in large numbers 
from either pluripotent stem cells [177] or from circulating monocytes [178]. These microglia-
like cells can be engrafted into the mouse brain, then maintaining microglia-specific gene 
signatures [52]. Niche-specific microenvironmental cues such as IL-34, CSF1 and TGF-β in 
the CNS are indispensable for achieving this goal [66, 67, 179]. Transplantation of these 
microglia-like cells into the mouse brain could therefore be a potent therapeutic intervention. 
Moving forward, studying patient-specific microglia in different pathological contexts using 
these approaches is urgently needed. It is also important to note that microglia-like cells are 
distinct from embryonic yolk-sac derived microglia in terms of immune metabolism, 
phagocytosis and cytokine production. Furthermore, understanding specific cellular and 
molecular pathways that regulate or imprint repopulating microglia-like cell identity after 
depleting dysregulated microglia across different brain regions is of great importance. 
Apart from microglia in the CNS, conventional systemic administration of compounds such as 
the drugs targeting CSF1R (PLX3397 or PLX5622) can also influence circulating monocytes 
and other tissue resident macrophages. Interpreting results and potential clinical translation 
using these methods should thus be considered with caution. Nanoparticles, ranging from 10 
to 1000 nm, have been increasingly used in the field of drug development and they offer the 
ability to deliver potential drugs or molecules to specific brain regions in order to achieve 
therapeutic actions. Directly delivering drugs into the CNS holds promise by avoiding potential 
phagocytosis and other side-effects in the periphery [180]. 
Since a variety of brain diseases exhibit marked sex differences, and that sex differences in 
microglia have been recently well established, these differences cannot be ignored in future 
studies. Microglial research should thus include both sexes in order to understand complex 
intrinsic factors including immune-related genes, epigenetic modifiers and environmental 
influences. Better understanding of the cellular and molecular differences in microglia between 
sexes is thus crucial to potential development of sex-targeted therapies for improving the 
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